Gina Wentling   Posted in News    Feb 9th, 2017

NeuroPointDX Partners with Ovid Therapeutics to Identify Biomarkers for Angelman Syndrome

Together, Ovid and NeuroPointDX will use metabolomics data to better understand the rare neuro-genetic disorder known as Angelman Syndrome. NeuroPointDX’s metabolomics technology will be used in Ovid’s phase 2 STARS trial of its drug candidate, OV101.

Read more